Home›Stock Screener›Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals Share Price Today | Stock Price & Aarey Drugs & Pharmaceuticals Share Screener

AAREYDRUGS Pharmaceuticals
Live Share Price NSE
₹104.07
▲ 0.22 (0.21%)
2026-10-05 00:00:00
Live Share Price BSE
₹103.25
▲ 0.20 (0.19%)
2026-10-05 00:00:00

As of October 5, 2026, the live Aarey Drugs & Pharmaceuticals share price (NSE: AAREYDRUGS) is ₹104.07 on NSE and ₹103.25 on BSE, up 0.21% from the previous close, with shares trading between ₹100.50 and ₹106.51 in today's trading session, and a 52-week range of ₹50.75–₹104.07. Check AAREYDRUGS 52-week performance for the annual price range and momentum. Use the Aarey Drugs & Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Aarey Drugs & Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹421 and net income of ₹4, with EBITDA of ₹13, an operating margin of 2.0% and a profit margin of 1.0%.

Aarey Drugs & Pharmaceuticals Market Cap ₹294.46 Cr.
AAREYDRUGS P/E Ratio (TTM) 75.90
Aarey Drugs & Pharmaceuticals P/B Ratio 1.90
EPS (TTM) ₹1.39
Dividend Yield -
Debt to Equity 0.24
AAREYDRUGS 52 Week High ₹104.07
Aarey Drugs & Pharmaceuticals 52 Week Low ₹50.75
Operating Margin 2.00%
Profit Margin 0.95%
AAREYDRUGS Revenue (TTM) ₹421.00
EBITDA ₹13.00
Net Income ₹4.00
Total Assets ₹291.00
Total Equity ₹139.00

Aarey Drugs & Pharmaceuticals Share Price Chart

Track the current stock price of Aarey Drugs & Pharmaceuticals with an interactive chart. Analyse AAREYDRUGS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Aarey Drugs & Pharmaceuticals stock quote in one place.

The quote of ₹104.07 sits between the 52-week low of ₹50.75 and the 52-week high of ₹104.07, and the latest session moved 0.21% from the previous close.

Aarey Drugs & Pharmaceuticals Company Profile - Fundamental Screener

Screen Aarey Drugs & Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AAREYDRUGS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE198H01019.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE198H01019

Aarey Drugs & Pharmaceuticals Balance Sheet Screener

Screen AAREYDRUGS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2025, total assets were ₹291, down from ₹303 in 2024.

Latest statistics put total assets at ₹291 and shareholder funds at ₹139, with a leverage ratio of 0.24.

Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

Assets

Total Assets 291 303 291 245 233 194 146 170 143 125
Current Assets 266 283 271 219 218 181 133 157 130 117
Fixed Assets 16 13 14 15 14 12 12 12 12 8

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 3 4 6 5 3 2 2 1 2 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 139 133 117 114 99 92 87 80 49 37
Share Capital 29 28 25 25 23 23 23 23 18 17
Reserves & Surplus 105 100 87 86 73 67 61 55 30 20

Aarey Drugs & Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Aarey Drugs & Pharmaceuticals income statement and profit fundamentals. Analyze AAREYDRUGS quarterly results. Aarey Drugs & Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹421 and net profit was ₹4, equal to earnings per unit of ₹1.50, at an operating margin of 2%.

In that period expenses were ₹408, interest cost ₹6 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹472 and net profit of ₹4.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 421 472 484 403 422 495 355 307 359 353 399 249 216
Expenses 408 465 471 391 411 481 344 297 347 342 386 245 212

Operating Costs and Margins

EBITDA 13 7 13 11 11 14 12 10 12 11 13 4 4
Operating Profit % 2.00% 2.00% 1.00% 1.00% 2.00% 2.00% 1.00% 1.00% 2.00% 2.00% 2.00% 0.00% 1.00%
Depreciation 3 3 2 2 2 2 1 1 1 1 1 1 1
Interest 6 5 5 4 3 2 2 2 2 2 4 2 2

Profit and Earnings

Profit Before Tax 4 5 6 5 6 10 8 7 9 8 8 2 1
Tax 1 2 2 1 2 4 2 1 2 2 3 1 0
Net Profit 4 4 4 5 4 7 7 6 7 6 6 1 1
EPS 1.50 1.39 1.42 1.84 1.49 2.72 2.79 2.48 2.80 2.64 3.03 0.77 0.65

Aarey Drugs & Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen AAREYDRUGS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹10.

Over the same period, investing activities used ₹6 and financing activities used ₹5.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities 10 -3 -1 1 6 3 1 -20 1 6
Investing Activities -6 -2 0 -3 -3 -1 -1 -1 -5 -3

Financing and Net Cash

Financing Activities -5 6 1 2 -3 -2 -3 23 4 -2
Net Cash Flow 0 1 1 -1 0 0 -3 2 -1 2

Aarey Drugs & Pharmaceuticals Shareholding Pattern Screener

See Aarey Drugs & Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Aarey Drugs & Pharmaceuticals promoter holding and ownership changes for AAREYDRUGS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 37.71%, foreign institutions 4.18%, domestic institutions 1.62% and the public 43.71%, spread across 14,188 shareholders.

The shareholder count was 14,188 in 2026-Mar, compared with 13,478 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Aug 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 37.71% 37.71% 42.79% 44.80% 44.80% 44.80% 39.06% 45.28%

Institutional Investors

FII Holding 4.18% 4.80% 4.41% 2.34% 1.97% 1.13% 3.86% 3.40%
DII Holding 1.62% 1.62% 1.49% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 43.71% 41.66% 38.26% 45.79% 46.60% 47.01% 45.40% 47.14%
Other Holding 12.78% 14.20% 13.04% 7.07% 6.63% 7.06% 11.69% 4.18%
Shareholder Count 14,188 13,478 13,480 16,257 15,796 14,897 14,063 16,821

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Aarey Drugs & Pharmaceuticals. Aarey Drugs & Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.10 0.75%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Aarey Drugs & Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Aarey Drugs & Pharmaceuticals stock. Check AAREYDRUGS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Aarey Drugs & Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Aarey Drugs & Pharmaceuticals Market Events Screener - Corporate Actions

Get Aarey Drugs & Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Aarey Drugs & Pharmaceuticals stock events that may affect AAREYDRUGS share price, along with derivatives, futures and options activity and sector gainers.

13 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.

It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 30, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-30 2026-09-30 Annual General Meeting NA 4.31%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 3.29%
2026-05-30 2026-05-30 Quarterly Result Announcement NA -0.81%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 0.14%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -2.10%
2025-09-29 2025-09-29 Annual General Meeting NA 11.95%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -3.93%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 0.96%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -3.23%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -9.71%
2024-09-30 2024-09-30 Annual General Meeting NA -0.82%
2023-12-29 2023-12-29 Annual General Meeting NA 10.20%
2023-12-29 2023-12-29 Extraordinary General Meeting NA 10.20%

Aarey Drugs & Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen AAREYDRUGS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Aarey Drugs & Pharmaceuticals Company Announcements - News & Reports Screener

Screen AAREYDRUGS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 5, 2026.

The next most recent announcements are dated October 5, 2026 and October 5, 2026.

Date Update Actions
2026-10-05 Disclosure under Regulation 30A of LODR -
2026-10-05 Disclosure under Regulation 30A of LODR -
2026-10-05 Disclosure under Regulation 30A of LODR -
2026-10-02 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-10-02 Revised Outcome Of Board Meeting Dated 06-08-2026 Approved In Board Meeting 30-09-2026 -
2026-10-02 Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 30-09-2026 -
2026-09-23 Closure of Trading Window -
2026-09-11 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements)Regulations 2015 -
2026-09-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-08 Reg. 34 (1) Annual Report. -
2026-09-08 Notice Of 36Th Annual General Meeting Of The Company For FY 2025-26 -
2026-09-08 Intimation Of Book Closure -
2026-09-05 Board Meeting Outcome for Outcome Of Board Meeting Held On 05Th September 2026 -
2026-08-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Unaudited Financial Results For The Quarter Ended 30Th June 2026 -
2026-08-14 Board Meeting Outcome for Outcome Of Board Meeting Held On Friday 14Th August 2026 -
2026-08-07 Board Meeting Intimation for Intimation Of Board Meeting -
2026-08-06 Board Meeting Outcome for Allotment Of Equity Shares Pursuant To Conversion Of Warrants -
2026-07-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-06-26 Closure of Trading Window -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹104.07, within a 52-week range of ₹50.75 to ₹104.07. The P/E ratio is 75.90 and the P/B ratio is 1.90, with earnings per unit of ₹1.39. Market capitalisation stands at ₹294.46 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.